Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Non Operating Income: 2011-2024

Historic Non Operating Income for China Pharma Holdings (CPHI) over the last 14 years, with Dec 2024 value amounting to -$147,499.

  • China Pharma Holdings' Non Operating Income rose 28.53% to -$23,337 in Q3 2025 from the same period last year, while for Sep 2025 it was $45,066, marking a year-over-year increase of 127.01%. This contributed to the annual value of -$147,499 for FY2024, which is 54.89% up from last year.
  • China Pharma Holdings' Non Operating Income amounted to -$147,499 in FY2024, which was up 54.89% from -$326,998 recorded in FY2023.
  • China Pharma Holdings' Non Operating Income's 5-year high stood at -$147,499 during FY2024, with a 5-year trough of -$538,966 in FY2021.
  • Its 3-year average for Non Operating Income is -$299,454, with a median of -$326,998 in 2023.
  • In the last 5 years, China Pharma Holdings' Non Operating Income crashed by 86.83% in 2021 and then skyrocketed by 54.89% in 2024.
  • Over the past 5 years, China Pharma Holdings' Non Operating Income (Yearly) stood at -$288,484 in 2020, then slumped by 86.83% to -$538,966 in 2021, then climbed by 21.36% to -$423,864 in 2022, then increased by 22.85% to -$326,998 in 2023, then skyrocketed by 54.89% to -$147,499 in 2024.